Oruka Therapeutics, Inc. (ORKA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$96.02-5.32%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ORKA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Total Revenues | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.0 | 3.2 | 5.0 |
| R&D Expenses | 129.0 | 100.6 | 75.1 | 1.0 | 4.7 | 13.8 | 5.0 | 1.8 | 4.2 | 14.1 | 12.3 | 7.1 | 5.6 | 2.9 | 1.1 | 2.3 |
| Operating Income | (155.1) | (122.1) | (88.1) | (7.3) | (10.6) | (19.3) | (9.8) | (5.8) | (8.1) | (18.7) | (16.6) | (11.5) | (9.7) | (6.9) | (4.3) | (7.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | 1.5 | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Interest & Investment Income | 22.2 | 16.6 | 5.9 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 22.2 | 16.6 | 4.4 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | (105.4) | (83.7) | — | — | (19.3) | (9.7) | (5.6) | (8.0) | (18.6) | — | — | — | (6.9) | (4.3) | (5.4) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | (0.0) | (0.2) | (0.0) | (0.1) | 0.0 | 0.0 | 0.0 | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (132.9) | (105.4) | (83.7) | (5.3) | (9.9) | (19.3) | (9.7) | (5.5) | (7.9) | (18.5) | (16.4) | (11.4) | (9.7) | (6.9) | (4.3) | (5.4) |
| Per Share | ||||||||||||||||
| Basic EPS | — | — | (3.87) | (0.37) | (0.69) | (1.39) | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | — | — | (3.87) | (0.37) | (0.69) | (1.39) | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | — | — | 16.8 | 14.4 | 14.4 | 13.9 | — | — | — | — | — | — | 20.5 | 8.6 | 2.2 | — |
| Diluted Weighted Avg Shares | — | — | 16.8 | 14.4 | 14.4 | 13.9 | — | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | (7.3) | (10.6) | (19.3) | (9.8) | (5.8) | (8.1) | (18.7) | (16.6) | (11.4) | (9.7) | (6.9) | (4.3) | (6.8) |
| EBIT | (155.1) | (122.1) | (88.1) | (7.3) | (10.6) | (19.3) | (9.8) | (5.8) | (8.1) | (18.7) | (16.6) | (11.5) | (9.7) | (6.9) | (4.3) | (7.4) |
| Effective Tax Rate | — | — | — | — | — | 0.0% | 0.1% | 3.0% | 0.4% | 0.3% | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.